CBS 2019
CBSMD教育中心
English

DAPT Duration

科研文章

荐读文献

Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study

Clinical TrialVolume 7, Issue 1, January 2014

JOURNAL:JACC: Cardiovascular Imaging Article Link

Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes : Insights From PROSPECT

Inaba S, Mintz GS, Maehara A et al. Keywords: CSA; DC; EEM; FF; FT; IVUS; MLA; NC; NCL MACE; RI; ROC; TCFA; ThCFA; VH; cardiovascular events; cross-sectional; dense calcium; external elastic membrane; fibrofatty; fibrotic; intravascular ultrasound; minimal lumen area; necrotic core; nonculprit lesion major adverse cardiac event(s); receiver-operating characteristic; remodeling; remodeling index; thick-cap fibroatheroma; thin-cap fibroatheroma; virtual histology

FULL TEXT PDF